


MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. St. Joseph Regional Medical Center, Inc.</p> <p>2. 504 Sixth Street Lewiston, ID 83501</p>	<p>In accordance with letter dated October 24, 2018.</p> <p>3. License number: 11-27371-01 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: March 31, 2023</p> <p>5. Docket No.: 030-32211 Reference No.:</p>
--	---	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 600 millicuries total	C. For any use permitted by 10 CFR 35.300.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
11-27371-01

Docket or Reference Number
030-32211

Amendment No. 14

- | | | | |
|---|--|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| D. Any byproduct material permitted in 10 CFR 35.400 | D. Sealed Sources (3M, Model 6500 Series; Amersham, Model 6702; 6711; 6733; CDCS.J3; SIAK.3158; BEBIG, Model 125.S06; Best Industries, Model 2300; 81-01; International Brachytherapy, Model 103L; 125IL; IsoStar Texas, Model IS-125; Isotope Products Laboratories, Model 67-6500 Series; 67-800 Series; 67-820 Series; North American Scientific, Model MED-3631; MED-3633; Syncor/Cardinal Health, Model BT-125-1; Theragenics, Model 200) | D. 2 curies total | D. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| E. Strontium-90 | E. Sealed Sources (Amersham, Model 0922 ML) | E. 30 millicuries per source and 30 millicuries total | E. For storage only. |
| F. Uranium- depleted in Uranium-235 | F. Metal | F. 999 kilograms total | F. For use as shielding in a linear accelerator. |

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at St. Joseph Regional Medical Center, 415 Sixth Street, Lewiston, Idaho.
11. The Radiation Safety Officer (RSO) for this license is Douglas Heidorn, Ph.D.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
11-27371-01

Docket or Reference Number
030-32211

Amendment No. 14

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

<u>Authorized User(M.D.,D.O.,etc.)</u>	<u>Material and Use</u>
Edward Abraham, M.D.	35.300; 35.400
Kent Anderson, M.D.	35.300, 35.400
Theresa Pagliuca, M.D.	Parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV
Paul Sanchirico, M.D.	35.100, 35.200, oral administration of sodium iodide in quantities less than or equal to 33 millicuries
Mirosław Sochanski, M.D.	35.200
Gregory R. Spurling, M.D.	35.100, 35.200
Michael Whisenant, M.D.	35.100, 35.200

C. The following individuals are authorized users for nonmedical uses as indicated:

<u>Non-Medical Use</u>	<u>Material and Use</u>
Kent Anderson, M.D.	Depleted uranium as shielding in a linear accelerator
Douglas Heidorn, Ph.D.	Cesium-137 for functionality tests of instruments
Paul Sanchirico, M.D.	Depleted uranium as shielding in a linear accelerator

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
11-27371-01

Amendment No. 14

Docket or Reference Number
030-32211


13. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

- A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months, or at such other intervals as specified.
- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.
- C. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- D. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
- E. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- F. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
11-27371-01Docket or Reference Number
030-32211

Amendment No. 14

- G. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- H. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for 3 years.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
11-27371-01

Amendment No. 14

Docket or Reference Number
030-32211

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 3, 2012 excluding procedures(ML12290A673)
- B. E-mail with attachments dated October 12, 2012 (ML12290A737)
- C. Emails with attachments dated March 18, 2013 excluding procedures (ML13078A146)
- D. Letter dated October 24, 2016 (ML16313A036)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

/RA/

Date: November 19, 2018

By: _____

Michelle R. Simmons
Region 4